ÂÜÀòÂÒÂ×

James Hardiman has a diverse range of work experience in the technology and investment industries. James started their career in 2013 as a Principal at DCVC (Data Collective), where they worked until 2016. In 2016, they became a Partner at the same company.

In 2017, they joined Recursion Pharmaceuticals as an Investor and Board Observer.

In 2018, James became an Investor and Board Observer at Q-CTRL.

In 2020, they took on multiple positions as an Investor and Board Director at Lumafield, Gradle Inc., and Stealth Robotics Company.

In 2021, they became an Investor and Board Director at Shennon Biotechnologies, and an Investor and Board Observer at Amogy.

In 2022, they continued their involvement as an Investor and Board Director at Stealth TechBio Company and an Investor and Board Observer at Stealth TechBio Company.

James Hardiman has a Bachelor of Science degree in Engineering Physics from the University of California, Berkeley. James also holds a Master of Business Administration (MBA) degree from The University of Chicago Booth School of Business.